Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05177211 | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | PHASE2 | ACTIVE NOT_RECRUITING | 25 | — | — | Mar 1, 2022 | Apr 1, 2026 | Apr 17, 2026 | 3 | United States |
Response rate of fedratinib in MDS/MPN and CNL. Investigators will measure the proportion of patients achieving a clinical response from baseline to week 24 as defined by Complete Response (CR), Partial Response (PR) or Clinical Benefit (CB) by modified MDS/MPN IWG Proposed response criteria.
| Arm | Type | Description |
|---|---|---|
| Treatment with Fedratinib | EXPERIMENTAL | Participants will taken Fedratinib by mouth once a day every day of each 28 day cycle. |
| Name | Type | Description |
|---|---|---|
| Fedratinib Pill | DRUG | Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day. |
Inclusion Criteria: * Patient must understand and voluntarily sign an ICF prior to any study-related assessments/ procedures being conducted * 18 years of age or older on day of signing informed consent. * Morphologically confirmed diagnosis of one of the following in accordance with WHO (2016) dia...